0000000000653230

AUTHOR

Johanna Tischer

showing 3 related works from this author

Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic …

2016

Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (HCT) is a treatment for CLL that can give long disease control. Even with the availability of kinase and BCL2 inhibitors, HCT is still performed in fit patients (pts) with high-risk CLL. Almost exclusively, outcomes on matched related and unrelated donor transplantations in CLL have been published. Recently, mismatched related donors are gaining interest because of the better outcome of haploidentical HCT with post-transplantation cyclophosphamide (PTCY). Methods: All pts with CLL who received a first allogeneic HCT with a mismatched related donor and whose data were available in the EBMT registry were analyzed. Medi…

medicine.medical_specialtybusiness.industryChronic lymphocytic leukemiaIncidence (epidemiology)medicine.medical_treatmentImmunologyRetrospective cohort studyContext (language use)Cell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryTransplantationAutologous stem-cell transplantationInternal medicineCohortmedicinebusinessBlood
researchProduct

Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogeno…

2020

The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients ≥55 years LFS was best with FLAMSA-Chemo without significant differences…

OncologyCancer Researchmedicine.medical_specialtyTransplantation ConditioningMedizinGraft vs Host Disease03 medical and health sciencesMyelogenous0302 clinical medicineRefractoryhemic and lymphatic diseasesInternal medicinemedicineHumansIn patientBusulfanAgedRetrospective StudiesAcute leukemiabusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseTransplantationLeukemia Myeloid AcuteLeukemiaOncology030220 oncology & carcinogenesisRelapsed refractoryStem cellbusiness030215 immunologyLeukemia & Lymphoma
researchProduct

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell t…

2012

Based on molecular aberrations, in particular the NPM1 mutation (NPM1(mut)) and the FLT3 internal tandem duplication (Flt3-ITD), prognostic subgroups have been defined among patients with acute myeloid leukemia with normal karyotype. Whereas these subgroups are known to play an important role in outcome in first complete remission, and also in the indication for allogeneic stem cell transplantation, data are limited on their role after transplantation in advanced disease. To evaluate the role of molecular subgroups of acute myeloid leukemia with normal karyotype after allogeneic stem cell transplantation beyond first complete remission, we analyzed the data from 141 consecutive adults (medi…

MaleOncologyTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantation0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationNuclear ProteinsMyeloid leukemiaInduction ChemotherapyHematologyMiddle Aged3. Good healthFludarabineTreatment OutcomeLeukemia Myeloid030220 oncology & carcinogenesisAcute DiseaseFemaleNucleophosminmedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationAdolescentPrimary Induction FailureKaryotypeDisease-Free SurvivalYoung Adult03 medical and health sciencesInternal medicinemedicineHumansTransplantation HomologousAgedSalvage Therapybusiness.industryMinimal residual diseaseSurgeryTransplantationfms-Like Tyrosine Kinase 3Multivariate AnalysisMutationTransplantation ConditioningOriginal Articles and Brief ReportsbusinessFollow-Up Studies030215 immunology
researchProduct